Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIA-102 intraperitoneal therapy trial in MSS advanced gastric or pancreatic cancer with malignant ascites
jRCT2073220017Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GAIA-102 and pembrolizumab in gastric cancer (GC) and pancreatic cancer (PC) (8 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Dose-limiting toxicity occurrence, Adverse events and 1 more. Started Oct 2022; status: recruiting.
02
Drugs
GAIA-102pembrolizumab
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2073220017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073220017.